Last reviewed · How we verify
Treatment with either metoprolol or carvedilol
Treatment with either metoprolol or carvedilol is a Small molecule drug developed by Bispebjerg Hospital. It is currently FDA-approved.
Treatment with either metoprolol or carvedilol, marketed by Bispebjerg Hospital, holds a significant position in the cardiovascular drug market. The key composition patent expiring in 2028 provides a clear timeline for potential generic competition, which is a key strength. The primary risk lies in the competitive landscape, where the entry of generics post-patent expiry could erode market share and revenue.
At a glance
| Generic name | Treatment with either metoprolol or carvedilol |
|---|---|
| Sponsor | Bispebjerg Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cardioprotection in AML (PHASE2)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial (NA)
- Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment with either metoprolol or carvedilol CI brief — competitive landscape report
- Treatment with either metoprolol or carvedilol updates RSS · CI watch RSS
- Bispebjerg Hospital portfolio CI